Tianjin Pharmaceutical Da Ren Tang Approves Sale of 13% Stake in Tianjin TSKF Pharma; Shares Surge 10%

MT Newswires09-30

Tianjin Pharmaceutical Da Ren Tang Group (SHA:600329, SGX:T14) approved the sale of a 13% stake in Tianjin TSKF Pharma to Haleon China for 1.75 billion yuan, according to a filing with the Singapore Exchange on Friday.

Following the sale of shares, the company will retain a 12% stake in the company.

Shares of the pharmaceutical company surged nearly 10% in China and nearly 7% in Singapore in recent trade.

Price (SGD): S$35.36, Change: S$+3.1, Percent Change: +9.58%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment